Loading
A phase 1/2 trial of Ifinatamab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) is a phase 1/2 interventional study registered as NCT07630974 by Merck Sharp & Dohme LLC, with 134 participants planned, started 2026-07-06 and due to reach its primary completion in 2031-08-17. Interventions recorded: Ifinatamab Deruxtecan.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.